Cellworks Expands Evidence for Predicting Chemo-Immunotherapy Benefit in NSCLC
Cellworks has presented new evidence supporting the predictive validity of its mechanistic AI platform for early-stage non-small cell lung cancer (NSCLC) at the AACR 2026 conference. The study adds to the understanding of how the platform can predict benefits from chemo-immunotherapy in this patient population.
New study presented at AACR 2026 supports the predictive validly of Cellworks’ mechanistic AI platform in early-stage NSCLC
SAN DIEGO, CA, UNITED STATES, April 22, 2026 /EINPresswire.com/ — Cellworks Group Inc., the leader in Personalized Therapy …